title: Pharmaceutical approval update.
abstract: Vortioxetine (Brintellix) for major depressive disorder; ustekinumab (stelara) for psoriatic arthritis; and dabrafenib mesylate (Tafinlar) for metastatic melanoma.
authors.forename: Marvin M
authors.initials: MM
authors.lastname: Goldenberg